临床试验/NCT02126904

NCT02126904Unknown不适用

Comparison of the Time to Recurrence After Ranibizumab or Aflibercept Loading for Age-related Macular Degeneration

Yokohama City University Medical Center1 个研究点分布在 1 个国家目标入组 200 人开始时间: 2012年1月最近更新: 2014年4月30日

适应症

干预措施

试验速览

阶段: 不适用
发起方: Yokohama City University Medical Center
入组人数: 200
试验地点: 1
主要终点: Time to recurrence after induction phase

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The investigators compared the time to recurrence after ranibizumab or aflibercept loading in patients with AMD.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Retrospective

入排标准

年龄范围: 50 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•They must have had BCVA better than 20/400 and had three consecutive induction treatment of ranibizumab or aflibercept.

排除标准

•patients with eye diseases that could potentially influence the visual acuity of the studied eye, such as glaucoma, macular hole, diabetic retinopathy, or rhegmatogenous retinal detachment.

研究组 & 干预措施

IVR group

干预措施: IVA group (Drug)

结局指标

主要结局

Time to recurrence after induction phase

时间窗: More than 3 months from baseline

Time frame depends on patients because recurrence time is different.

次要结局

未报告次要终点

研究者

发起方

Yokohama City University Medical Center

申办方类型

Other

责任方

Principal Investigator

主要研究者

Maiko Inoue

Associate Professor

Yokohama City University Medical Center

研究点 (1)

Loading locations...

相似试验

已完成

4 期

Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend RegimenCentral Retinal Vein Occlusion

NCT02274259Anders Kvanta40

已完成

4 期

Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMDNeovascular Age-related Macular Degeneration

NCT01958918Novartis Pharmaceuticals712

已完成

3 期

Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein OcclusionBranch Retinal Vein Occlusion

NCT01599650Novartis Pharmaceuticals455

进行中（未招募）

1 期

Investigating the rate of clearance of ranibizumab and aflibercept from the eyeMedDRA version: 17.0 Level: PT Classification code 10064930 Term: Age-related macular degeneration System Organ Class: 10015919 - Eye disordersAge-related macular degenerationMedDRA version: 17.0 Level: LLT Classification code 10067791 Term: Wet macular degeneration System Organ Class: 10015919 - Eye disorders

EUCTR2012-005500-18-GBKing's College Hospital NHS Foundation Trust62

终止

不适用

Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)Retinal Vein Occlusion

NCT01875770Johns Hopkins University47